DeCure's autonomous Cancer AI scientist is researching a drug-repurposing hypothesis for prostate carcinoma — screening already-approved drugs against its 39-gene Open Targets disease module to publish open-access research. Research is fast; the path to publication is funded in milestone stages.
Disease moduleProstate carcinoma maps to a 39-gene Open Targets module — the target space DeCure's AI scientist screens approved drugs against.
DeCure.ai methodSignature reversal (LINCS) plus network proximity (STRING) rank already-approved drugs likely to perturb this module — the same engine that produces DeCure.ai's repurposing hypotheses.
Repurposing thesisScreening approved medicines against this disease module, then publishing the evidence for the strongest candidate. Known pharmacology and human exposure data make the first question sharper — they do not establish safety or efficacy in a new indication.
Research record
01
ResearchComing soon
Candidate research + dossier — target rationale, drug-repurposing thesis and evidence pack.proof: Published dossier + on-chain hash
02
ValidationComing soon
In-vitro biological validation at a contract research org (CRO).proof: CRO contract + in-vitro report
03
Peer review & paperComing soon
Peer-reviewed paper published open-access (preprint + journal).proof: DOI + open-access link + on-chain hash
Current lead
No approved-drug candidate for prostate carcinoma is corroborated in the literature DeepSearch retrieved. Some conditions are managed with non-pharmacological care — a device, surgery or physical therapy — rather than a medicine; that may be the case here, or the literature we found may simply be too sparse yet to support a drug-repurposing angle.
Molecular view
MDM4 regulator of p53 (MDM4) — MDM4 is one of the genes genetically linked to this disease in Open Targets — shown as context, not as a drug target we're pursuing: no approved-drug candidate for this disease is yet corroborated in the literature we found.
Loading structure…
helix sheet 3~{s}drag to rotate · scroll to zoom
RCSB Protein Data Bank · entry 6Q9Y · 1.2 Å · ligand 7-methoxy-~{N}-[(3~{S})-1-(4-methylphenyl)pyrrolidin-3-yl]-1~{H}-indole-3-carboxamide (HRQ). Experimental structure, not a prediction.
What the evidence adds up to
Androgen ablation for prostate carcinoma was described 60 years ago, but its optimal use remains controversial. A critical review of the literature found data supporting early initiation of androgen ablation for patients with locally advanced or lymph node positive disease. No data support a particular PSA trigger point or doubling time for starting therapy after failure of local radical treatment. Combined results from 27 prospective randomised trials of total androgen blockade showed a modest survival benefit: the average absolute 5-year survival rate improved by 3% (a 10% reduction in the risk of dying), with a 95% confidence interval between 0.4% and 6.0%. Intermittent therapy improved quality of life during the off-treatment interval, but uncertainty remained about its long-term effect on survival. The review concluded that androgen ablation is not curative and has a substantial adverse impact on quality of life, especially with prolonged use.
A retrospective cohort study of 2,311 men aged 55–74 diagnosed with nonmetastatic prostate carcinoma during 1971–1984 compared three management strategies. Ten-year overall survival estimates were: expectant management 42% (95% CI 38–46%), radiotherapy 52% (95% CI 46–58%), and radical prostatectomy 69% (95% CI 67–71%). Disease-specific survival estimates were: expectant management 75% (95% CI 71–79%), radiotherapy 67% (95% CI 61–73%), and radical prostatectomy 86% (95% CI 84–88%). The authors cautioned that direct comparisons between treatment groups were inadvisable because of large differences in distributions of important prognostic factors among men who selected each strategy.
A Society of Urologic Oncology position statement noted that patients with hormone-refractory prostate carcinoma are a very diverse group and that few studies have provided definitive treatment answers. A multidisciplinary panel developed a treatment algorithm based on literature review and expert opinion, including hormonal manipulations, chemotherapeutic options, and adjunctive therapies. The statement concluded that although significant progress has been made in understanding and treating hormone-refractory disease, earlier interventions would be ideal and better therapeutic approaches to prolong survival are necessary.
What is still missing are prospective randomised trials directly comparing management strategies for nonmetastatic disease with adequate control for prognostic factors, definitive evidence on the long-term survival effect of intermittent versus continuous androgen ablation, and better treatments for hormone-refractory disease that go beyond the modest survival gains and quality-of-life trade-offs documented so far.
Evidence
Retrieved by DeepSearch across 234,678,978 indexed works and resolved on OpenAlex — ranked by citations, including the results that did not work.
Cancer · 2000 · 105 citations
Hormone therapy for patients with prostate carcinoma
AbstractBACKGROUND: Androgen ablation as a treatment for patients with prostate carcinoma was described 60 years ago. Despite the long pedigree for this treatment, the optimal use of androgen ablation therapy remains extremely controversial. Monitoring the level of prostate specific antigen (PSA) has created a dramatic shift in the population of patients in whom androgen ablation is initiated. This has resulted in a number of changing concepts of treatment. Patients with recurrent prostate carcinoma after the failure of local therapy are now diagnosed with recurrent disease on the basis of a rising PSA level. These patients have a median life expectancy of 10-15 years compared with 3 years for patients who present with metastatic disease. This means that the systemic side effects of androgen ablation and the impact on quality of life have become more important. Controversies exist with respect to the timing of therapy, the use of intermittent androgen ablation, and the role of total androgen blockade. METHODS: A critical review of the literature, with an emphasis on quality of life and recent publications, was performed. RESULTS: Data support the early initiation of androgen ablation for patients with locally advanced or lymph node positive prostate carcinoma. There are no data supporting a particular PSA trigger point or a PSA doubling time for the initiation of androgen ablation therapy after the failure of local radical therapy. The combined results of 27 prospective randomized trials of total androgen blockade support the finding of a modest survival benefit for patients who undergo androgen ablation with combined therapy. The average, absolute 5-year survival rate was improved by 3% (a 10% reduction in the risk of dying), with a 95% confidence interval between 0.4% and 6.0%. Intermittent therapy resulted in an improved quality of life in the off-treatment interval. Uncertainty remains with respect to the long term effect of intermittent androgen ablation therapy on patient survival. This is being studied in a prospective intergroup trial comparing continuous therapy with intermittent therapy carried out by the National Cancer Institute Criteria/Canadian Uro-Oncology Group and the Southwest Oncology Group. CONCLUSIONS: Androgen ablation therapy is an effective treatment for patients with advanced prostate carcinoma. It has serious limitations, however. Although it improves patient survival, it is not curative, and it is associated with a substantial adverse impact on the quality of life for patients, particularly when its use is prolonged. The advent of intermittent therapy may reduce this impact. The real challenge, however, is to develop better means to avert hormone-refractory prostate carcinoma and better treatments for patients with hormone-refractory disease when it occurs.
Outcomes for men with clinically nonmetastatic prostate carcinoma managed with radical prostactectomy, external beam radiotherapy, or expectant management
AbstractBACKGROUND: With a lack of data from randomized trials, the optimal management of men with nonmetastatic prostate carcinoma is controversial. The authors sought to define the outcomes of three common strategies for managing patients with nonmetastatic prostate carcinoma: expectant management, radiotherapy, and radical prostatectomy. METHODS: The authors conducted a retrospective cohort study with standardized collection of key prognostic data, including centralized assignment of Gleason grades from original biopsy specimens. Participants included all Connecticut hospitals (the expectant management cohort) and three academic medical centers in other states (the radiotherapy and surgery cohorts). Two thousand three hundred eleven consecutive men ages 55-74 years who were diagnosed during 1971-1984 with nonmetastatic prostate carcinoma and were treated at the participating sites were included. RESULTS: Kaplan-Meier estimates with 95% confidence intervals (95% CI) of overall survival at 10 years for each cohort were as follows: expectant management cohort, 42% of patients (95% CI, 38-46%); radiotherapy cohort, 52% of patients (95% CI, 46-58%); and radical prostatectomy cohort, 69% of patients (95% CI, 67-71%); for disease specific mortality, the estimates were as follows: expectant management cohort, 75% of patients (95% CI, 71-79%); radiotherapy cohort, 67% of patients (95% CI, 61-73%); and radical prostatectomy cohort, 86% of patients (95% CI, 84-88%). There were large differences in distributions of important prognostic factors among men in the different treatment groups. CONCLUSIONS: These data provide precise estimates of the outcomes of patients who have been treated with different modalities for nonmetastatic prostate carcinoma in the recent past. Direct comparisons of outcomes between treatment groups are inadvisable because of the different characteristics of patients who select these alternative management strategies.
Society of Urologic Oncology position statement: Redefining the management of hormone‐refractory prostate carcinoma
AbstractBecause patients with hormone-refractory prostate carcinoma are a very diverse group, management of these patients represents a unique challenge. Despite much research, to the authors' knowledge few studies published to date have provided definitive treatment answers. The Society of Urologic Oncology (SUO) convened a multidisciplinary panel of urologists, oncologists, and radiation oncologists to develop a treatment algorithm for patients with hormone-refractory prostate carcinoma. The resulting treatment outline was based on a review of the literature review and on the expert opinions of the panelists. The current article provided a logical progression of treatment choices that included hormonal manipulations, chemotherapeutic options, and adjunctive therapies. Future clinical trials and therapies were also discussed by the authors. Management strategies should be targeted toward the individual patient. Although significant progress has been made in understanding and treating hormone-refractory prostate carcinoma, earlier interventions would be ideal and better therapeutic approaches to prolong survival are necessary.
Disease module: DeepOracle (Open Targets). Structures: RDKit from PubChem SMILES. Literature: retrieved by DeepSearch across 234,678,978 indexed works (targeted per-candidate search), resolved on OpenAlex.
DeCure is a research and publication project, not medical advice and not a treatment. "DeCure for X" describes a research goal, not a claim that a cure exists. Backing a cure is a contribution to fund the research — it is not an investment, and confers no yield, royalty, equity or IP ownership. Papers are published open-access by the DeCure.ai DAO.
